Medicina (Kaunas). 2019 Jun 28;55(7). pii: E321. doi: 10.3390/medicina55070321.
Kılıç B1, Kılıç M2.
- 1 Dept of Child Neurology, University of Health Sciences, Derince Training and Research Hospital, 41900 Kocaeli, Turkey. betulklc82 at gmail.com.
- 2 Dept of Neurosurgery, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, 34371 Istanbul, Turkey. kilicnrs at gmail.com.
6 month trial on migraine youths of average age 13 who had < 20ng level of vitamin D
Started with 2,000 IU for 2 months, then 600 to 1,000 IU daily for 4 months
Expect that they would have had even better success by
Using larger dose sizes so as to get most of them >30 ng
- Larger doses especially for those who were heavier/overweight
Adding Magnesium and Zinc
Also expect that the Migraines would have been reduced in a few weeks if they had used a loading dose of Vitamin D
Note: Both Migraines and Cluster headaches in adults have been very succesfully treated by Vitamin D and Magnesium
Headache category has the following
|Cadmium||0.36 ug||0.09 ug||4X MORE if decrease|
|Iron||0.97 ug||0.48 ug||2X MORE if decrease|
|Lead||1.48 ug||0.78 ug||2X MORE if decrease|
|Magnesium||10.6 ug||34.5 ug||3.5X LESS if increase|
|Zinc||0.24 ug||5.77 ug||24X LESS if increase|
Pages listed in BOTH the categories Headache and Magnesium
- Migraine headaches cut in half by 4,000 IU of vitamin D – RCT Sept 2018
- Acute Migraine 35 times more likely if low Magnesium levels – May 2016
- Migraine headaches quickly reduced with Magnesium – Meta-analysis Jan 2016
- Cluster headaches substantially reduced by 10,000 IU of Vitamin D in 80 percent of people
- Migraines may be due to lack of lack of Magnesium in half of sufferers – May 2012
- Headache with vitamin D may mean you need Magnesium
BACKGROUND AND OBJECTIVES:
Vitamin D deficiency and insufficiency are related with many neurological diseases such as migraine. The aim of this study was to investigate whether pediatric migraine is associated with vitamin D deficiency and the effect of vitamin D therapy on the frequency, duration, severity of migraine attacks, and Pediatric Migraine Disability Assessment (PedMIDAS).
MATERIALS AND METHODS:
We retrospectively examined the patients' levels of calcium, phosphorus, parathyroid hormone, alkaline phosphatase, and 25-OH vitamin D of 92 pediatric migraine patients. The patients were divided into two groups: Group 1, which had low vitamin D levels and received vitamin D therapy, and group 2, which had normal vitamin D levels and did not receive vitamin D therapy. Migraine severity measured by the visual analog scale (VAS), migraine frequency, and duration as well as scores on the PedMIDAS questionnaire were compared with regard to the 25-OH vitamin D levels. In addition, pre- and posttreatment pedMIDAS scores, VAS, migraine frequency, and duration were compared with baseline values.
A total of 34.7% patients had vitamin D insufficiency (vitamin D levels between 10 and 20 ng/mL), whereas 10.8% had vitamin D deficiency (vitamin D levels < 10 ng/mL). Migraine frequency, migraine duration, and PedMIDAS scores were significantly higher in the group 1 than group 2 (p = 0.004, p = 0.008, and p = 0.001). After vitamin D therapy at sixth months of supplementation, migraine duration was reported statistically significant shorter (p < 0.001) and the migraine frequency, VAS scores, and pedMIDAS scores were statistically significant lower compared with baseline values in group 1 (p < 0.001).
We found a marked correlation between pediatric migraine and vitamin D levels. Vitamin D therapy was beneficial in migraine pediatric patients.